Chronic obstructive pulmonary disease

Local Research Study on COPD Flare-Ups Now Available to Residents in the Wyomissing Area

Retrieved on: 
Monday, December 11, 2023
Other Health, Research, Men, Consumer, Clinical Trials, Science, Women, Biotechnology, Seniors, FDA, Other Science, Health, Chronic obstructive pulmonary disease, COPD, Mortality, Smoker, Patient, Multimedia, Hospital, Death, Pharmaceutical industry, Nursing, Sanofi

A new research study on chronic obstructive pulmonary disease (COPD) is now available in Wyomissing, Pa., for a potential treatment for reducing COPD exacerbations.

Key Points: 
  • A new research study on chronic obstructive pulmonary disease (COPD) is now available in Wyomissing, Pa., for a potential treatment for reducing COPD exacerbations.
  • The AERIFY-2 study from Sanofi will evaluate if the investigational treatment, itepekimab, reduces dangerous symptom flare-ups in both current and former smokers with moderate-to-severe COPD.
  • The local setting provides residents of Wyomissing, Reading, and surrounding communities the option to participate in clinical studies close to home.
  • With a global network of over 150 research sites, Care Access supports research studies conducted by 14 of the top 15 biopharmaceutical companies.

Research Study on COPD Flare-Ups Now Available to Mooresville Residents

Retrieved on: 
Monday, December 11, 2023
Other Health, Research, Men, Pharmaceutical, Consumer, Clinical Trials, Science, Cardiology, Women, Biotechnology, Seniors, Health, Chronic obstructive pulmonary disease, COPD, Mortality, Smoker, Multimedia, Hospital, Death, Pharmaceutical industry, Nursing, Sanofi

A new research study on chronic obstructive pulmonary disease (COPD) is now available in Mooresville, N.C., for a potential treatment for reducing COPD exacerbations.

Key Points: 
  • A new research study on chronic obstructive pulmonary disease (COPD) is now available in Mooresville, N.C., for a potential treatment for reducing COPD exacerbations.
  • The AERIFY-2 study from Sanofi will evaluate if the investigational treatment, itepekimab, reduces dangerous symptom flare-ups in both current and former smokers with moderate-to-severe COPD.
  • Sever Surdulescu, the Care Access Research Investigator for this study in Mooresville.
  • With a global network of over 150 research sites, Care Access supports research studies conducted by 14 of the top 15 biopharmaceutical companies.

Research Study on COPD Flare-Ups Now Available to Rock Hill Residents

Retrieved on: 
Monday, December 11, 2023
Biotechnology, FDA, Health, Women, Seniors, Pharmaceutical, Men, Research, Consumer, Science, Clinical Trials, Chronic obstructive pulmonary disease, COPD, Mortality, Smoker, Multimedia, Hospital, Death, Pharmaceutical industry, Nursing, Sanofi

A new research study on chronic obstructive pulmonary disease (COPD) is now available in Rock Hill, S.C., for a potential treatment for reducing COPD exacerbations.

Key Points: 
  • A new research study on chronic obstructive pulmonary disease (COPD) is now available in Rock Hill, S.C., for a potential treatment for reducing COPD exacerbations.
  • “Approximately one in fourteen adults in South Carolina have COPD, which is higher than the national average,” said Dr. Arun Adlakha, the Care Access Research Investigator for this study in Rock Hill.
  • Care Access opened its doors in Rock Hill in collaboration with local community leaders and healthcare providers seeking to make clinical research more accessible.
  • The community-based setting provides Rock Hill residents the option to participate in clinical studies close to home.

Research Study on COPD Flare-Ups Now Available to Greater Houston Residents

Retrieved on: 
Monday, December 11, 2023
FDA, Health, Clinical Trials, Research, Pharmaceutical, Science, Disease, Chronic obstructive pulmonary disease, COPD, Risk, Mortality, Smoker, Quality of life, Multimedia, Hospital, Death, Sanofi, Greater Houston

A new research study on chronic obstructive pulmonary disease (COPD) is now available in the Greater Houston, Texas, area for a potential treatment for reducing COPD exacerbations.

Key Points: 
  • A new research study on chronic obstructive pulmonary disease (COPD) is now available in the Greater Houston, Texas, area for a potential treatment for reducing COPD exacerbations.
  • The AERIFY-1 study from Sanofi will evaluate if the investigational treatment, itepekimab, reduces dangerous symptom flare-ups in former smokers with moderate-to-severe COPD.
  • The study is offered at Care Access locations in Houston, Conroe, Lake Jackson, and Webster.
  • The convenient settings throughout the Houston area provide local residents the option to participate in clinical studies close to home.

Research Study on COPD Flare-Ups Now Available to Greater Cincinnati Residents

Retrieved on: 
Monday, December 11, 2023
Men, Research, Other Health, Pharmaceutical, Consumer, Clinical Trials, Science, Biotechnology, Women, Seniors, FDA, Health, Other Science, Chronic obstructive pulmonary disease, COPD, Mortality, Smoker, Multimedia, Hospital, Death, Pharmaceutical industry, Nursing, Sanofi, Cincinnati metropolitan area

A new research study on chronic obstructive pulmonary disease (COPD) is now available in Hamilton and Middletown, Ohio, for a potential treatment for reducing COPD exacerbations.

Key Points: 
  • A new research study on chronic obstructive pulmonary disease (COPD) is now available in Hamilton and Middletown, Ohio, for a potential treatment for reducing COPD exacerbations.
  • The AERIFY-1 study from Sanofi will evaluate if the investigational treatment, itepekimab, reduces dangerous symptom flare-ups in former smokers with moderate-to-severe COPD.
  • Care Access opened its doors in the Greater Cincinnati area in collaboration with local community leaders and healthcare providers seeking to make clinical research more accessible.
  • With a global network of over 150 research sites, Care Access supports research studies conducted by 14 of the top 15 biopharmaceutical companies.

Respiratory Disease Testing Market Size & Trends Analysis 2023 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 28, 2023
Health, General Health, COPD, Prevalence, Medtronic, BD (company), Application, Respiratory disease, Patient, Occupational lung disease, Airway management, USD, Chronic obstructive pulmonary disease, CareFusion, CT scan, Diagnosis, Growth, Respironics, Asthma, NIV, Medical device, Pharmaceutical industry, Medical imaging

The "Respiratory Disease Testing Market Size, Share & Trends Analysis Report By Product (Imaging Tests, Respirometers, Blood Gas Tests), By End-use, By Application, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Respiratory Disease Testing Market Size, Share & Trends Analysis Report By Product (Imaging Tests, Respirometers, Blood Gas Tests), By End-use, By Application, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global respiratory disease testing market size is expected to reach USD 7.75 billion by 2030, registering a CAGR of 2.8% from 2023 to 2030
    The market is driven by the rising prevalence of respiratory diseases.
  • Along with technological advancements, use of digital radiography (X-ray) and advanced portable spirometers is gaining momentum in the respiratory disease testing/diagnostics market.
  • These players are strong brands in the market as they have elaborate product portfolios in respiratory disease diagnostics market

RION, Mayo Clinic, and the U.S. Army Medical Research Institute for Chemical Defense Receive $2.4M Department of Defense Award to Advance Exosome-Based Research in Pulmonary Therapeutics

Retrieved on: 
Monday, November 20, 2023
Other Health, Research, Technology, Defense, Hospitals, Clinical Trials, Science, Nanotechnology, Biotechnology, Veterans, Health, Military, COPD, Prevalence, Disease, ICD, Mortality, DSM-IV codes, Patient, Multimedia, Regenerative medicine, Exosome, FDA, Particulates, Wound healing, Smoke, Inhalation, Therapy, Chronic obstructive pulmonary disease, Veteran, Splenic infarction, Chemical defense, Injury, Mayo Clinic, Fire, Pharmaceutical industry

RION, a leading clinical-stage regenerative medicine company, today announced that it will collaborate with Mayo Clinic and the U.S. Army Medical Research Institute for Chemical Defense (ICD) on a $2.4M grant awarded from the Department of Defense.

Key Points: 
  • RION, a leading clinical-stage regenerative medicine company, today announced that it will collaborate with Mayo Clinic and the U.S. Army Medical Research Institute for Chemical Defense (ICD) on a $2.4M grant awarded from the Department of Defense.
  • View the full release here: https://www.businesswire.com/news/home/20231120732351/en/
    RION, located in Rochester, MN, brings extensive experience in developing and commercializing biological therapeutics.
  • The harmful gases, vapors, and/or particulate matter released by fires in war zones typically results in severe lung-induced morbidity and mortality.
  • Recent discoveries have proven that exosomes, nano-sized vesicles known for their regenerative capabilities, play a crucial role in the human body.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET

Retrieved on: 
Monday, November 20, 2023
Health, Infectious Diseases, COVID-19, Clinical Trials, Research, Science, Pharmaceutical, Sale, Heart, Southampton General Hospital, Pediatrics, Patient, Conference, Doctor of Philosophy, Viral, Webcast, Safety, RSV, Human, Respiratory system, MBBS, Federal, Chronic obstructive pulmonary disease, Texas A&M University, O'Driscoll (surname), Dean (education), Respiratory Medicine, Pharmacokinetics, University, FRCP, Fast Track, Asthma, Medication, Infection, FERS, Urinary tract infection, Virology, Ageing, Upper respiratory tract infection, Viral load, Clinical trial, Tax, HBV, FDA, Vaccine, Faculty, OMERS, HCV, State Administrative Expenses, Pharmaceutical industry, Life insurance, Cryptocurrency, Pfizer, Cantab, FIDSA, FAAP, Medicine, MD

(NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2023.

Key Points: 
  • (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2023.
  • For the twelve months ended September 30, 2023, total revenue was $79.2 million compared to $86.2 million for the same period in 2022.
  • The decrease in the quarter and in year-over-year revenue is due to a decline in AbbVie’s sales of MAVYRET®/MAVIRET®.
  • Non-cash interest expense was $3.2 million for the three months ended September 30, 2023 and $5.1 million for the twelve months ended September 30, 2023.

Artificial Organs Global Market Report 2023: A Potential $17.7 Billion Opportunity by 2027 - Benefits of Artificial Organs Over Traditional Transplants Drive Market Expansion - ResearchAndMarkets.com

Retrieved on: 
Monday, November 13, 2023
Hospitals, Health, Surgery, Medical Supplies, Kidney disease, COPD, Artificial organ, Prevalence, Cardiomyopathy, Investment, Liver cancer, Pelvic floor dysfunction, End organ damage, Idiopathic pulmonary fibrosis, Pulmonary hypertension, Viral, Inflammation, Chronic obstructive pulmonary disease, Blood, Organ transplantation, Ageing, Infection, Myocarditis, Growth, Cystic fibrosis, Moyamoya disease, Organic, Accident, Sonova, LivaNova, Smoking, Blood pressure, Aquaculture, Dentistry

This report is a comprehensive study of the global artificial organs market.

Key Points: 
  • This report is a comprehensive study of the global artificial organs market.
  • It describes the artificial organs market, segmented by product type and region.
  • Based on product type, the market is segmented into artificial hearts, artificial kidneys, artificial lungs, artificial pancreases, and cochlear implants.
  • Emerge more prepared and stay at the forefront of the global artificial organs market.

Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Monday, November 13, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Contract research organization, Business analyst, Scleroderma, Benaroya Research Institute, Clinical trial, Administration, Research and development, Inflammation, Strategic planning, Interleukin 7, Alopecia areata, Research fellow, G&A, Ulcerative colitis, Thymic stromal lymphopoietin, Atopic dermatitis, TSLP, R, CMC, Chronic obstructive pulmonary disease, IL-7, Hidradenitis suppurativa, Asthma, Allergy, Pharmaceutical industry, Cryptocurrency

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights.
  • "In the third quarter, Zura Bio made significant progress in its strategic planning across various key areas, including Clinical, Regulatory, CMC, and Translational Science.
  • This progress positions Zura Bio for clinical trial readiness in 2024," stated Dr. Someit Sidhu, Chief Executive Officer of Zura Bio.
  • Zura Bio anticipates that its cash and cash equivalents are sufficient to fund its planned operations into 2026.